Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Cisplatin Ototoxicity
Interventions
DRUG

Dexamethasone Phosphate

"0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level."

Trial Locations (1)

Unknown

Clalit Health Services, Haifa

Sponsors
All Listed Sponsors
lead

Meir Medical Center

OTHER

NCT01372904 - Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment | Biotech Hunter | Biotech Hunter